Annotation of rs2230199

Genotype GG is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotypes CC + CG.

No significant differences in mean visual acuity (units = letters), mean visual acuity change from baseline (units = letters), >= 15-letter increase from baseline (%), mean number of injections, retinal thickness (%, units = um), mean change in total foveal thickness from baseline (units = um), dry on optical coherence tomography (%), leakage on fluorescein angiography (%) or mean change in lesion size from baseline (units = disc area) after 1 year of treatment were seen between genotypes. p <= 0.01 was considered statistically significant to adjust for multiple comparisons.

From Publication

Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology. 2013. Hagstrom Stephanie A et al.

PMID:23337555 PMCID:PMC3633658 DOI:10.1016/j.ophtha.2012.11.037

Gene

Variant

rs2230199

Phenotype Category

Efficacy

Association Significance

The study reports this association is not significant

PharmGKB ID

1183491605

Score
More info on scoring

-2.5

Evidence for Clinical Annotations

This annotation has not been used as evidence for any clinical annotations.

Study Parameters

1. Study type

cohort

Study size

834

Association p-value

= 0.03

Allele frequency

C=0.74

Population description

Study Cohort: p-value refers to mean visual acuity.

2. Study type

cohort

Study size

834

Association p-value

= 0.07

Allele frequency

C=0.74

Population description

Study Cohort: p-value refers to dry on optical coherence tomography.

3. Study type

cohort

Study size

834

Association p-value

= 0.28

Allele frequency

C=0.74

Population description

Study Cohort: p-value refers to mean change in lesion size from baseline.

4. Study type

cohort

Study size

834

Association p-value

= 0.30

Allele frequency

C=0.74

Population description

Study Cohort: p-value refers to mean number of injections.

5. Study type

cohort

Study size

834

Association p-value

= 0.34

Allele frequency

C=0.74

Population description

Study Cohort: p-value refers to mean visual acuity change from baseline.

6. Study type

cohort

Study size

834

Association p-value

= 0.51

Allele frequency

C=0.74

Population description

Study Cohort: p-value refers to retinal thickness

7. Study type

cohort

Study size

834

Association p-value

= 0.67

Allele frequency

C=0.74

Population description

Study Cohort: p-value refers to mean change in total foveal thickness from baseline.

8. Study type

cohort

Study size

834

Association p-value

= 0.72

Allele frequency

C=0.74

Population description

Study Cohort: p-value refers to >= 15-letter increase from baseline.

9. Study type

cohort

Study size

834

Association p-value

= 0.85

Allele frequency

C=0.74

Population description

Study Cohort: p-value refers to leakage on fluorescein angiography.

Note: Alleles in PharmGKB are mapped to the positive chromosomal strand. Therefore, variants in genes on the "minus" strand (eg. VKORC1) are complemented in PharmGKB annotations.

History

No history available.